FDA
-
-
-
-
-
-
-
Artelo Biosciences gets U.S. patent allowance for ART27.13 drug
-
-
-
-
-
-
-
Artelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial Results
-
-
-
-
-
-
-
Artelo Biosciences reports $12.9 million loss for fiscal 2025
-
-
-
-
-
-
-
Artelo reports positive interim phase 2 data for cancer treatment ART27.13
-
-
-
-
-
-
-
Artelo Biosciences receives European patent allowance for ART27.13
-
-
-
-
-
-
-
Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12
-
-
-
-
-
-
-
Artelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update
-
334,271 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


